Eurecon Verlag: Pharma Trend Awards Best Pharmaceutical Companies and the Most Innovative Products 2021
The winner for the award "The Golden Tablet®" has been determined - BioNTech. In addition to the company's research activity, a large product pipeline with many innovations is decisive for the award, as well as the quality of the products. The ranking "Best Pharmaceutical Companies Germany 2021" was also published: Roche Pharma, Lilly, Bristol-Myers Squibb, Novartis Pharma and Amgen occupy places one to five in the Pharma Trend Image & Innovation Award survey.
Thirteen other winners were able to enjoy the award "Most Innovative Product". These include in the Rx category (prescription drugs): the COVID-19 vaccine Comirnaty® from BioNTech and Tolak® for the treatment of actinic keratoses from Pierre Fabre. Exeltis is awarded for both the oral contraceptive Slinda® and DeflaGyn® for the treatment of cervical dysplasia / erosions. In the Orphan Drugs category, Gilead Sciences' hepatitis D drug Hepcludex®, Kyowa Kirin's Poteligeo® for the treatment of mycosis fungoides and Sézary syndrome, and Incyte's Pemazyre® for the treatment of cholangiocarcinoma win.
In the Specialty Care segment, the prostate cancer drug Erleada® from Janssen-Cilag receives an award. The food supplement ImmunoBON® for allergy therapy by Bencard is the winner in the OTC category. The app MyIUS from Jenapharm, which accompanies users of intrauterine systems, was chosen in the Digital Health Applications category. Roche Diagnostics won in the Diagnostics category with the SARS-CoV-2 Rapid Antigen Test on the one hand, and the Avenio NGS Oncology Assay on the other. In the category Leap Innovations - Treatment of COVID-19, Formycon lands in first place followed by Ethris and Pieris Pharmaceuticals in second and third place.
The publication of the ranking and the presentation of the subject-specific awards took place on 14 September 2021 as a hybrid event in the Ehrensaal of the Deutsches Museum.
Further information on the ranking and the awards at https://pharma-trend.com/en/pharma-award/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005795/en/
Contact information
Eurecon Verlag GmbH
Dr. Dieter Jung, +49 8151 909801
CEO
Dieter.jung@eurecon.de
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NILIT Announces Strategic Expansions, Including a Joint Venture with Shenma in China18.4.2024 05:30:00 CEST | Press release
NILIT, the global leader in high-performance Nylon 6.6 fibers for the apparel industry and leader in sustainability, that owns the broadest line of sustainable Nylon 6.6 products, is announcing a new joint venture with Shenma Industry Co., Ltd. (hereinafter referred to as Shenma), a subsidiary of China Pingmei Shenma Group, a global leader in the industrial Nylon 6.6 market and a leading supplier to the automotive industry around the world. This new partnership represents a significant expansion of production capacity within China, also demonstrating NILIT’s ongoing commitment to support the growth of global customers and brands. This expansion is highlighted by multiple investments and cooperation designed to enhance production capabilities and deliver more innovative solutions to the textile industry. “We are pleased to unveil this new greenfield joint venture in China with Shenma to introduce differentiated state-of-the-art technologies to support the local market,” says Ilan Melame
The Office of Health Economics: Adult Vaccination Programmes Deliver Socio-economic Benefits up to 19 Times Initial Investment, According to New Report18.4.2024 01:01:00 CEST | Press release
A new report published today reveals that adult vaccination programmes can return up to 19 times their initial investment when the full spectrum of economic and societal benefits is valued. The 19x return is equivalent to up to USD 4,637 in net monetary benefits to society per individual full vaccination course. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240417519822/en/ Learn more about the economic benefits of investing in adult immunisation programmes in a new study by the Office of Health Economics (OHE). Graphic: OHE The study, a first-of-its-kind analysis of adult immunisation programmes by the Office of Health Economics (OHE) and commissioned by IFPMA (1), looked at four adult vaccines across ten countries where they are available to determine the wider economic and social impact. Focusing on vaccines that protect against influenza (flu), pneumococcal disease, respiratory syncytial virus (RSV), and herpes zoster (
Saudi Arabia Highlights Investment Initiatives in Tourism at International Hospitality Investment Forum 17.4.2024 19:51:00 CEST | Press release
The Saudi Ministry of Tourism is currently taking a prominent stage at the International Hospitality Investment Forum (IHIF), presenting a unique opportunity for global investors to dive into the thriving tourism landscape of the Kingdom. With the spotlight on the Tourism Investment Enablers Program (TIEP), that was recently announced, Saudi Arabia is aggressively pushing towards its Vision 2030 goal of being a top global tourism destination for investors and tourists alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240417879947/en/ Mr. Mahmoud Abdullhadi, Deputy Minister of Destinations Enablement. (Photo: AETOSWire) This strategic presentation comes at a time when Saudi Arabia's tourism sector celebrates an incredible milestone of 100 million visitors in 2023, seven years ahead of schedule, marking a significant stride towards economic diversification and emphasizing the sector's growing contribution to the nationa
Kai Tak Sports Park Limited and ASM Global Begin Countdown to Unveiling of World’s Largest Sports Development in History17.4.2024 15:00:00 CEST | Press release
The Hong Kong Special Administrative Region Government, ASM Global and Kai Tak Sports Park Limited (KTSPL) — which is a subsidiary of New World Development — as part of a multiyear strategy, have announced a late winter testing period for Kai Tak marking the culmination of a near decade-long record $4 billion project creating the premiere sports, recreation, entertainment complex on Earth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240417546819/en/ PLAY BALL – Kai Tak Sports Park, the largest and most ambitious sports-development and entertainment district in the world, is being managed by ASM Global. (Photo: Business Wire) ASM Global, as the lead operator, has been on the ground in Hong Kong working for over five years supporting the design, programming and construction of Kai Tak Sports Park, featuring many of the world’s most advanced state-of-the-art venues and is now prepping for pre-opening activities in advance of
Qualcomm Announces Quarterly Cash Dividend17.4.2024 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.85 per common share, payable on June 20, 2024, to stockholders of record at the close of business on May 30, 2024. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Our proven solutions drive transformation across major industries, and our Snapdragon® branded platforms power extraordinary consumer experiences. Building on our nearly 40-year leadership in setting industry standards and creating era-defining technology breakthroughs, we deliver leading edge AI, high-performance, low-power computing, and unrivaled connectivity. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing business, QTL, and the vast majority o